<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158700</url>
  </required_header>
  <id_info>
    <org_study_id>17387</org_study_id>
    <secondary_id>I8X-MC-JECD</secondary_id>
    <secondary_id>2019-001156-18</secondary_id>
    <secondary_id>KEYNOTE-961</secondary_id>
    <nct_id>NCT04158700</nct_id>
  </id_info>
  <brief_title>A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer</brief_title>
  <official_title>Phase 1b/2 Study of LY3200882 and Pembrolizumab in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of
      transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and
      effective in participants with cancer that has spread to other parts of the body.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The withdrawal is due to a strategic realignment and is not related to any particular safety or
    efficacy concern.
  </why_stopped>
  <start_date type="Anticipated">December 5, 2019</start_date>
  <completion_date type="Anticipated">May 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 6 Weeks</time_frame>
    <description>Number of Participants with DLT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Disease Progression or Death (Estimated at up to 12 Months)</time_frame>
    <description>ORR: Percentage of Participants with CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3200882 in Combination With Pembrolizumab</measure>
    <time_frame>Baseline through Week 13</time_frame>
    <description>PK: Cmax of LY3200882 in Combination With Pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated at up to 12 Months)</time_frame>
    <description>DoR</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>LY3200882 and Pembrolizumab (Dose Level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3200882 and Pembrolizumab (Dose Level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3200882 and Pembrolizumab Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with urothelial carcinoma, non-small cell lung cancer, or hepatocellular carcinoma: LY3200882 administered orally twice in combination with pembrolizumab administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3200882</intervention_name>
    <description>LY3200882 administered orally</description>
    <arm_group_label>LY3200882 and Pembrolizumab (Dose Level 1)</arm_group_label>
    <arm_group_label>LY3200882 and Pembrolizumab (Dose Level 2)</arm_group_label>
    <arm_group_label>LY3200882 and Pembrolizumab Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered IV</description>
    <arm_group_label>LY3200882 and Pembrolizumab (Dose Level 1)</arm_group_label>
    <arm_group_label>LY3200882 and Pembrolizumab (Dose Level 2)</arm_group_label>
    <arm_group_label>LY3200882 and Pembrolizumab Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing
             on this study [for example, nivolumab, pembrolizumab, atezolizumab]

          -  Participants must be willing to have tumor biopsies

          -  Participants must have adequate organ function

          -  Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1

          -  Participants must be able to swallow tablets

          -  Participants with stable, previously treated brain metastases may participate if
             neurologic symptoms have resolved and participants have been off steroids for at least
             14 days

        Exclusion Criteria:

          -  Participants must not have moderate or severe cardiovascular disease

          -  Participants must not have active autoimmune disease (for example Crohn's disease,
             Hashimotos disease, etc)

          -  Participants must not have an active infection requiring treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon Hopital Jean Minjoz</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/advanced-cancer/JECD#?postal=</url>
    <description>A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TGF-beta</keyword>
  <keyword>Urothelial carcinoma</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>TGF- beta receptor type I inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

